<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An 11-year-old boy with <z:mpath ids='MPATH_458'>normal</z:mpath> visus and eye fundus, but with empty sella, growth hormone (GH) deficiency and <z:hpo ids='HP_0000863'>central diabetes insipidus</z:hpo> was found to have intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> with <z:e sem="disease" ids="C0030353" disease_type="Disease or Syndrome" abbrv="">papilloedema</z:e> after 6 months of catch-up growth under recombinant human GH (rhGH) replacement therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Withdrawal of rhGH therapy was associated with normalisation of intracranial pressure within 1 week </plain></SENT>
<SENT sid="2" pm="."><plain>Three months later, resumption of rhGH therapy at a lower dose was again followed by pronounced <z:mpath ids='MPATH_72'>growth acceleration</z:mpath>, but now without <z:e sem="disease" ids="C0030353" disease_type="Disease or Syndrome" abbrv="">papilloedema</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>CONCLUSION: Children with empty sella and GH deficiency may be prone to rhGH-induced <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumour cerebri</z:e> which appears to be rapidly reversible and dose-dependent </plain></SENT>
</text></document>